Tsai J F, Chang W Y, Jeng J E, Ho M S, Lin Z Y, Tsai J H
Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.
Liver. 1994 Apr;14(2):98-102. doi: 10.1111/j.1600-0676.1994.tb00055.x.
To investigate whether hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are risk factors for liver cirrhosis and hepatocellular carcinoma (HCC), a case-control study of 102 cirrhotic HCC patients, 102 sex-matched and age-matched patients with liver cirrhosis, and 102 matched patients with non-hepatic disease controls was performed. The prevalences of hepatitis B surface antigen (HBsAg) and antibody to HCV (anti-HCV) in HCC (70.5%, 39.2%) and liver cirrhosis (74.5%, 27.4%) were higher than controls (16.6%, 10.5%) (P = 0.0001). In HBsAg-negative patients, the prevalence of anti-HCV in cirrhotic HCC (66.6%) and liver cirrhosis (46.1%) was higher than in controls (10.5%; P = 0.0001). There was no such difference in HBsAg-positive patients. Multivariate analysis revealed that both HBsAg and anti-HCV were important risk factors for HCC (odds ratio, 6.52 and 4.59, respectively) and liver cirrhosis (odds ratio, 4.22 and 2.29, respectively). There was no difference in odds ratio when HCC and liver cirrhosis were compared. Our result implies that both HBV and HCV are independent risk factors for cirrhotic HCC and liver cirrhosis in Taiwan.
为了研究乙型肝炎病毒(HBV)和丙型肝炎病毒(HCV)感染是否为肝硬化和肝细胞癌(HCC)的危险因素,开展了一项病例对照研究,研究对象包括102例肝硬化HCC患者、102例性别和年龄匹配的肝硬化患者以及102例匹配的非肝病对照患者。HCC患者(70.5%,39.2%)和肝硬化患者(74.5%,27.4%)中乙肝表面抗原(HBsAg)和抗HCV抗体(抗-HCV)的流行率高于对照组(16.6%,10.5%)(P = 0.0001)。在HBsAg阴性患者中,肝硬化HCC患者(66.6%)和肝硬化患者(46.1%)的抗-HCV流行率高于对照组(10.5%;P = 0.0001)。在HBsAg阳性患者中则无此差异。多变量分析显示,HBsAg和抗-HCV均为HCC(优势比分别为6.52和4.59)和肝硬化(优势比分别为4.22和2.29)的重要危险因素。比较HCC和肝硬化时,优势比无差异。我们的结果表明,在台湾,HBV和HCV均为肝硬化HCC和肝硬化的独立危险因素。